Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $75.92M by Medicaid between Jan 2018 and Dec 2024, across 415 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
BALDWIN PARK, CA 91706
BALDWIN PARK, CA 91706
33aNPI1477608271assigned 01/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$75.92M
24GClaims2,173,374
24DCodes billed415
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#34 of 410
Median peer was paid$6.90M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 339,497 | $694K | |
| 2019 | 256,863 | $10.82M | |
| 2020 | 215,064 | $13.24M | |
| 2021 | 287,972 | $11.15M | |
| 2022 | 304,117 | $12.06M | |
| 2023 | 367,804 | $13.15M | |
| 2024incomplete | 402,057 | $14.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 54,544 | 50,408 | $20.93M |
| G0378 | Hospital observation service, per hour | 12% | 8,349 | 5,964 | $8.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.6% | 9,865 | 9,418 | $6.53M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 3.6% | 2,644 | 2,597 | $2.73M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 9,782 | 9,567 | $2.57M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 9,238 | 9,060 | $1.94M |
| 0450 | Emergency room services | 1.6% | 30,029 | 27,663 | $1.24M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 7,148 | 7,012 | $1.22M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 11,720 | 11,364 | $1.05M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 9,461 | 9,458 | $989K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 16,572 | 16,123 | $841K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 1,061 | 1,037 | $841K |
403 more codes
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.1% | 551 | $806K |
| 0002A | <1% | 17,467 | $687K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,263 | $665K |
| 0001A | <1% | 18,181 | $582K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,910 | $572K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,072 | $563K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 36,190 | $499K |
| 93971 | <1% | 2,120 | $498K | |
| 80051 | <1% | 109,450 | $470K | |
| 82565 | <1% | 128,706 | $468K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,330 | $461K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,601 | $457K |
| 86900 | <1% | 8,966 | $456K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 54,772 | $452K |
| 77080 | <1% | 4,768 | $451K | |
| 86885 | <1% | 6,418 | $421K | |
| 76830 | Ultrasound, transvaginal | <1% | 5,020 | $416K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,598 | $401K |
| 80061 | Lipid panel | <1% | 34,279 | $399K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 464 | $381K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,316 | $380K |
| 84460 | <1% | 84,039 | $339K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 10,860 | $334K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,717 | $320K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,529 | $318K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,528 | $310K |
| 94060 | <1% | 1,034 | $301K | |
| 72100 | <1% | 3,425 | $284K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 177 | $272K |
| 73630 | <1% | 4,951 | $269K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,565 | $264K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,559 | $264K |
| 73562 | <1% | 4,562 | $254K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,472 | $251K |
| 85027 | <1% | 53,358 | $239K | |
| 74183 | <1% | 743 | $235K | |
| 83970 | <1% | 6,021 | $232K | |
| 76641 | <1% | 2,682 | $230K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,885 | $221K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 294 | $220K |
| 73030 | <1% | 3,887 | $219K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,377 | $214K |
| 73610 | <1% | 4,030 | $205K | |
| 71250 | <1% | 1,521 | $194K | |
| 76770 | <1% | 2,338 | $193K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,890 | $192K |
| 82247 | <1% | 52,367 | $182K | |
| 84075 | <1% | 50,095 | $180K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 770 | $172K |
| 84450 | <1% | 45,360 | $165K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,144 | $161K |
| 76536 | <1% | 1,746 | $150K | |
| 82728 | <1% | 12,531 | $149K | |
| 73130 | <1% | 2,686 | $146K | |
| 83880 | <1% | 9,964 | $142K | |
| 84702 | <1% | 12,192 | $142K | |
| 86901 | <1% | 8,977 | $140K | |
| 84520 | <1% | 72,898 | $139K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,504 | $134K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,320 | $133K |
| 86780 | <1% | 10,694 | $130K | |
| 82947 | <1% | 66,720 | $129K | |
| 93970 | <1% | 329 | $128K | |
| 94726 | <1% | 649 | $128K | |
| 87505 | <1% | 1,223 | $126K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,489 | $125K |
| 87088 | <1% | 26,364 | $117K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,713 | $116K |
| 74018 | <1% | 2,130 | $111K | |
| 73502 | <1% | 1,894 | $108K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 135 | $107K |
| 85610 | <1% | 43,112 | $107K | |
| 73110 | <1% | 2,148 | $104K | |
| 82310 | <1% | 31,453 | $104K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,110 | $103K |
| 62323 | <1% | 389 | $101K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 979 | $101K |
| 82607 | <1% | 7,630 | $100K | |
| 94729 | <1% | 620 | $100K | |
| 99199 | Unlisted special service, procedure or report | <1% | 3,612 | $99K |
| 86141 | <1% | 8,765 | $97K | |
| 70486 | <1% | 978 | $97K | |
| 81003 | <1% | 60,209 | $93K | |
| 82043 | <1% | 17,143 | $91K | |
| 99285 | Emergency room visit (most serious) | <1% | 251 | $91K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,147 | $89K |
| 86803 | <1% | 6,808 | $87K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 114 | $86K |
| 83550 | <1% | 11,496 | $85K | |
| 81513 | <1% | 1,085 | $84K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,718 | $84K |
| 73140 | <1% | 1,831 | $81K | |
| 72141 | <1% | 460 | $80K | |
| 83690 | <1% | 23,598 | $78K | |
| 83735 | <1% | 23,173 | $73K | |
| 76642 | <1% | 969 | $73K | |
| 83520 | <1% | 3,975 | $66K | |
| 76801 | <1% | 1,045 | $65K | |
| 87340 | <1% | 7,446 | $65K | |
| 86480 | <1% | 1,187 | $64K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,986 | $63K |
| 83540 | <1% | 11,584 | $61K | |
| 70491 | <1% | 466 | $58K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,407 | $57K |
| 71101 | <1% | 783 | $57K | |
| 84484 | <1% | 18,614 | $56K | |
| 84153 | <1% | 3,441 | $54K | |
| 73080 | <1% | 1,125 | $54K | |
| 82746 | <1% | 4,198 | $53K | |
| 84439 | <1% | 6,725 | $53K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 549 | $53K |
| 82040 | <1% | 15,092 | $53K | |
| 73564 | <1% | 615 | $51K | |
| 0637 | <1% | 89,966 | $51K | |
| 76870 | <1% | 653 | $50K | |
| 76881 | <1% | 501 | $49K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,834 | $49K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 193 | $46K |
| 83721 | <1% | 5,146 | $46K | |
| 72040 | <1% | 886 | $45K | |
| 82105 | <1% | 3,040 | $45K | |
| 73590 | <1% | 1,028 | $45K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 629 | $43K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,084 | $42K |
| 87481 | <1% | 1,162 | $42K | |
| 82248 | <1% | 15,824 | $41K | |
| 93880 | <1% | 58 | $41K | |
| 72050 | <1% | 406 | $40K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,395 | $39K |
| 84403 | <1% | 1,645 | $38K | |
| 90686 | <1% | 3,265 | $37K | |
| 84100 | <1% | 14,311 | $35K | |
| 84165 | <1% | 3,061 | $33K | |
| 70496 | <1% | 135 | $33K | |
| 82570 | <1% | 6,688 | $32K | |
| 72197 | <1% | 63 | $30K | |
| 82378 | <1% | 1,626 | $30K | |
| 70498 | <1% | 131 | $30K | |
| 85379 | <1% | 5,390 | $30K | |
| 86317 | <1% | 2,283 | $30K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,396 | $29K |
| 86003 | <1% | 813 | $29K | |
| 83655 | <1% | 3,250 | $27K | |
| 83718 | <1% | 4,055 | $27K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,855 | $27K |
| 86762 | <1% | 2,231 | $27K | |
| 87040 | <1% | 9,737 | $27K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,036 | $26K |
| 83001 | <1% | 1,461 | $25K | |
| 86787 | <1% | 2,377 | $25K | |
| 83615 | <1% | 4,942 | $25K | |
| 77066 | Tomosynthesis, mammo | <1% | 199 | $25K |
| Z7502 | <1% | 867 | $24K | |
| 80076 | <1% | 2,983 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,312 | $23K |
| 84146 | <1% | 1,284 | $22K | |
| 86704 | <1% | 2,068 | $21K | |
| 73090 | <1% | 549 | $21K | |
| 74170 | <1% | 125 | $20K | |
| 84156 | <1% | 5,911 | $20K | |
| 86038 | <1% | 1,928 | $19K | |
| 83605 | <1% | 6,002 | $18K | |
| 73660 | <1% | 434 | $18K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 523 | $17K |
| 85652 | <1% | 9,418 | $17K | |
| 72131 | <1% | 200 | $17K | |
| 82784 | <1% | 920 | $17K | |
| 72070 | <1% | 246 | $17K | |
| 86923 | <1% | 236 | $16K | |
| 88342 | <1% | 230 | $15K | |
| 82465 | <1% | 4,518 | $15K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,483 | $15K |
| 84480 | <1% | 1,268 | $15K | |
| 87210 | <1% | 4,615 | $15K | |
| 85730 | <1% | 3,762 | $15K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 878 | $14K |
| 84132 | <1% | 3,991 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,466 | $14K |
| 84550 | <1% | 4,278 | $13K | |
| 87449 | <1% | 1,999 | $13K | |
| 83021 | <1% | 1,018 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,632 | $13K |
| 84270 | <1% | 633 | $13K | |
| 82550 | <1% | 4,233 | $13K | |
| 82077 | <1% | 2,206 | $13K | |
| 80197 | <1% | 1,046 | $12K | |
| 74178 | <1% | 124 | $12K | |
| 76380 | <1% | 295 | $12K | |
| 82670 | <1% | 416 | $12K | |
| P9021 | Red blood cells, each unit | <1% | 332 | $11K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 77 | $11K |
| 0250 | <1% | 9,714 | $11K | |
| 82950 | <1% | 2,707 | $11K | |
| 85014 | <1% | 5,708 | $10K | |
| 86765 | <1% | 840 | $10K | |
| 80306 | <1% | 1,476 | $9K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 133 | $9K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,252 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 977 | $9K |
| 73221 | <1% | 83 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 446 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,289 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 488 | $9K |
| 82677 | <1% | 497 | $9K | |
| 87186 | <1% | 2,379 | $8K | |
| 73060 | <1% | 150 | $8K | |
| 88341 | <1% | 44 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 484 | $8K |
| 84295 | <1% | 1,838 | $7K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,707 | $7K |
| 80179 | <1% | 1,298 | $7K | |
| 97161 | <1% | 1,187 | $7K | |
| 87324 | <1% | 904 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 253 | $7K |
| 85018 | <1% | 3,207 | $7K | |
| 70544 | <1% | 51 | $7K | |
| 82627 | <1% | 276 | $7K | |
| 86334 | <1% | 268 | $7K | |
| 0710 | <1% | 669 | $7K | |
| J3490 | Unclassified drugs | <1% | 4,997 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,724 | $6K |
| 87497 | <1% | 147 | $6K | |
| 73552 | <1% | 141 | $6K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 187 | $6K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,968 | $6K |
| 78306 | <1% | 49 | $6K | |
| 86336 | <1% | 498 | $5K | |
| 82951 | <1% | 396 | $5K | |
| 81015 | <1% | 1,545 | $5K | |
| 87081 | <1% | 2,777 | $5K | |
| 84163 | <1% | 460 | $5K | |
| 86431 | <1% | 1,062 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,743 | $5K |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 58 | $5K |
| 81329 | <1% | 58 | $4K | |
| 0258 | <1% | 3,376 | $4K | |
| 80164 | <1% | 507 | $4K | |
| 90715 | <1% | 190 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,024 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,473 | $4K |
| 87205 | <1% | 1,938 | $4K | |
| 90662 | <1% | 359 | $4K | |
| 86225 | <1% | 377 | $4K | |
| 83002 | <1% | 280 | $4K | |
| C1769 | Guide wire | <1% | 115 | $4K |
| 86304 | <1% | 310 | $4K | |
| 90656 | <1% | 391 | $4K | |
| 73560 | <1% | 221 | $4K | |
| 86677 | <1% | 621 | $4K | |
| 86335 | <1% | 155 | $4K | |
| 86364 | <1% | 285 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,638 | $3K |
| 82962 | <1% | 3,168 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,432 | $3K |
| 86708 | <1% | 315 | $3K | |
| 85046 | <1% | 914 | $3K | |
| 90674 | <1% | 231 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,885 | $3K |
| 82533 | <1% | 233 | $3K | |
| 86160 | <1% | 223 | $3K | |
| 0370 | <1% | 1,275 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 105 | $3K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 50 | $3K |
| 96367 | <1% | 249 | $3K | |
| 86665 | <1% | 229 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,937 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 556 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 844 | $2K |
| 72170 | <1% | 135 | $2K | |
| 94010 | <1% | 15 | $2K | |
| 82805 | <1% | 116 | $2K | |
| 88307 | <1% | 50 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,409 | $2K |
| 87631 | <1% | 106 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 834 | $2K |
| 73700 | <1% | 42 | $2K | |
| 0031A | <1% | 42 | $2K | |
| 82952 | <1% | 382 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,380 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 521 | $2K |
| 86735 | <1% | 148 | $2K | |
| 83993 | <1% | 65 | $1K | |
| 87070 | <1% | 392 | $1K | |
| 84155 | <1% | 455 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 48 | $1K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 119 | $1K |
| 87517 | <1% | 40 | $1K | |
| 86664 | <1% | 116 | $1K | |
| 86709 | <1% | 200 | $1K | |
| 72220 | <1% | 13 | $1K | |
| 84134 | <1% | 338 | $993.18 | |
| 87536 | <1% | 155 | $976.15 | |
| 92610 | <1% | 57 | $945.63 | |
| 84145 | <1% | 240 | $851.90 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 644 | $834.88 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 270 | $787.97 |
| 87522 | Neg quan hep c or qual rna | <1% | 89 | $777.51 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 130 | $688.14 |
| 82140 | <1% | 135 | $686.85 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 808 | $682.63 |
| 90688 | <1% | 60 | $650.41 | |
| 29125 | <1% | 60 | $645.68 | |
| 82150 | <1% | 158 | $552.40 | |
| 74022 | <1% | 123 | $551.84 | |
| 82977 | <1% | 160 | $546.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 646 | $523.97 |
| 80359 | <1% | 141 | $516.90 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 218 | $486.39 |
| 86360 | <1% | 274 | $476.04 | |
| 86308 | <1% | 154 | $457.15 | |
| 86769 | <1% | 14 | $443.13 | |
| 83010 | <1% | 38 | $437.00 | |
| 12001 | <1% | 63 | $425.49 | |
| 82024 | <1% | 12 | $425.00 | |
| 80324 | <1% | 141 | $422.84 | |
| 80053 | Comprehensive metabolic panel | <1% | 43 | $412.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 116 | $389.30 |
| 90749 | <1% | 94 | $385.37 | |
| 86359 | <1% | 274 | $376.98 | |
| 88304 | <1% | 156 | $368.20 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 15 | $341.41 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 41 | $334.58 |
| 3044F | <1% | 2,735 | $325.20 | |
| 0255 | <1% | 81 | $310.65 | |
| 97116 | <1% | 164 | $304.29 | |
| 86140 | <1% | 2,129 | $295.79 | |
| 80329 | <1% | 185 | $294.95 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 157 | $281.42 |
| 82390 | <1% | 39 | $272.53 | |
| 86301 | <1% | 102 | $269.00 | |
| 83529 | <1% | 17 | $268.04 | |
| 86256 | <1% | 79 | $259.81 | |
| 86696 | <1% | 13 | $254.20 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 338 | $250.99 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 128 | $239.16 |
| 82272 | <1% | 124 | $231.46 | |
| 85045 | <1% | 70 | $227.47 | |
| 83930 | <1% | 92 | $220.82 | |
| 82274 | <1% | 47 | $215.60 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 321 | $209.81 |
| 83935 | <1% | 98 | $198.88 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 23 | $193.68 |
| 80320 | <1% | 281 | $184.79 | |
| 86695 | <1% | 13 | $178.72 | |
| 0272 | <1% | 154 | $178.14 | |
| 89051 | <1% | 155 | $171.50 | |
| 10060 | <1% | 13 | $160.29 | |
| 87184 | <1% | 39 | $128.02 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 15 | $118.11 |
| 73100 | <1% | 86 | $114.65 | |
| 0320 | <1% | 14 | $110.07 | |
| 85384 | <1% | 14 | $90.00 | |
| 97162 | <1% | 12 | $88.23 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 83 | $69.04 |
| 82340 | <1% | 12 | $68.91 | |
| 76706 | <1% | 18 | $61.52 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 25 | $58.86 |
| 85049 | <1% | 13 | $48.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 13 | $43.93 |
| 87045 | <1% | 74 | $42.37 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 602 | $41.76 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 137 | $40.76 |
| 87185 | <1% | 37 | $31.37 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 62 | $29.26 |
| 87149 | <1% | 26 | $29.23 | |
| 87046 | <1% | 51 | $21.92 | |
| 86235 | <1% | 16 | $20.00 | |
| 12011 | <1% | 14 | $18.00 | |
| 82945 | <1% | 25 | $9.87 | |
| 80162 | <1% | 125 | $9.54 | |
| 80185 | <1% | 12 | $9.50 | |
| 84157 | <1% | 13 | $8.97 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 65 | $8.96 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 29 | $0.22 |
| 3052F | <1% | 167 | $0.03 | |
| 3051F | <1% | 317 | $0.02 | |
| V2632 | Posterior chamber intraocular lens | 0% | 213 | $0.00 |
| 80178 | 0% | 41 | $0.00 | |
| G0300 | Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes | 0% | 1,137 | $0.00 |
| 3074F | 0% | 126 | $0.00 | |
| 86300 | 0% | 64 | $0.00 | |
| 72146 | 0% | 39 | $0.00 | |
| G0156 | Services of home health/hospice aide in home health or hospice settings, each 15 minutes | 0% | 796 | $0.00 |
| G0155 | Services of clinical social worker in home health or hospice settings, each 15 minutes | 0% | 902 | $0.00 |
| 82985 | 0% | 24 | $0.00 | |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | 0% | 356 | $0.00 |
| 86376 | 0% | 12 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 14 | $0.00 |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | 0% | 949 | $0.00 |
| 72158 | 0% | 13 | $0.00 | |
| 74181 | 0% | 28 | $0.00 | |
| 70543 | 0% | 12 | $0.00 | |
| 3046F | 0% | 328 | $0.00 | |
| 86039 | 0% | 110 | $0.00 | |
| 3078F | 0% | 87 | $0.00 | |
| 73070 | 0% | 13 | $0.00 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 0% | 231 | $0.00 |
| 87338 | 0% | 16 | $0.00 | |
| 74220 | 0% | 13 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 57 | $0.00 |
| G0162 | Skilled services by a registered nurse (rn) for management and evaluation of the plan of care; each 15 minutes (the patient's underlying condition or complication requires an rn to ensure that essential non-skilled care achieves its purpose in the home health or hospice setting) | 0% | 68 | $0.00 |
| 87799 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPIERCE, MARGARET (EXECUTIVE DIRECTOR)